Literature DB >> 8342189

Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia.

P Rubba1, F Faccenda, S Di Somma, A Gnasso, N Scarpato, A Iannuzzi, G Nappi, A Postiglione, O De Divitiis, M Mancini.   

Abstract

BACKGROUND AND
PURPOSE: Low-density lipoprotein apheresis is currently used for the treatment of familial hypercholesterolemia, an inherited disorder of metabolism associated with premature development of cardiovascular disease. We wanted to evaluate cerebral blood flow velocity, cardiac output, and systemic vascular resistance in patients with familial hypercholesterolemia before and after low-density lipoprotein apheresis.
METHODS: Ten patients (age range, 14 to 46 years; 4 males, 6 females) with familial hypercholesterolemia (8 homozygotes, 2 heterozygotes) and 10 healthy control subjects of comparable age and sex distribution participated in the study. Low-density lipoprotein apheresis by dextran sulfate was performed in 8 patients (7 homozygotes, 1 heterozygote). Six patients (4 homozygotes, 2 heterozygotes) underwent a procedure of extracorporeal erythrocyte filtration with the same extracorporeal volume as for low-density lipoprotein apheresis, but with the exclusion of the passage of plasma through the dextran sulfate column. Cerebral blood flow velocity (transcranial Doppler), cardiac output, and systemic vascular resistance (electric bioimpedance cardiography) were determined by noninvasive techniques before and 1 day and 7 days after low-density lipoprotein apheresis or extracorporeal erythrocyte filtration. Plasma and blood viscosities were measured at the same time.
RESULTS: Before apheresis, mean and diastolic cerebral flow velocities were abnormally low in hypercholesterolemic patients (P < .01 and P < .02 vs healthy control subjects, respectively). After apheresis, low-density lipoprotein cholesterol was lowered by 40% to 60% from baseline, and cerebral blood flow velocities (mean, systolic, and diastolic velocities) were increased (P < .01). Cardiac output, systemic vascular resistance, and viscosity values were not significantly modified. Extracorporeal erythrocyte filtration (without passage of plasma through the dextran sulfate column) did not modify serum lipids, hemodynamic parameters, or viscosity values.
CONCLUSIONS: Low-density lipoprotein apheresis produces potentially useful hemodynamic effects. They are not adequately explained by changes in blood viscosity alone and might reflect a restoration of endothelium-mediated vasodilation, which is inhibited by high concentrations of low-density lipoprotein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8342189     DOI: 10.1161/01.str.24.8.1154

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  5 in total

1.  Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment.

Authors:  Kurt Derfler; Sabine Steiner; Helmut Sinzinger
Journal:  Wien Klin Wochenschr       Date:  2015-07-23       Impact factor: 1.704

2.  Hyperlipidemia disrupts cerebrovascular reflexes and worsens ischemic perfusion defect.

Authors:  Cenk Ayata; Hwa Kyoung Shin; Ergin Dileköz; Dmitriy N Atochin; Satoshi Kashiwagi; Katharina Eikermann-Haerter; Paul L Huang
Journal:  J Cereb Blood Flow Metab       Date:  2013-03-13       Impact factor: 6.200

3.  Correction of erythrocyte shape abnormalities in familial hypercholesterolemia after LDL-apheresis: does it influence cerebral hemodynamics?

Authors:  A Iannuzzi; G Bianciardi; F Faccenda; A Gnasso; N Scarpato; L Di Marino; G Iaccarino; C Simoes; G Sacchi; E Weber
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

4.  Doppler study of cerebral arteries in hypercholesterolemia.

Authors:  Mehdi Farhoudi; Kaveh Mehrvar; Naser Aslanabadi; Kamyar Ghabili; Nazila Rasi Baghmishe; Farzad Ilkhchoei
Journal:  Vasc Health Risk Manag       Date:  2011-03-31

5.  Resting brain perfusion and selected vascular risk factors in healthy elderly subjects.

Authors:  Otto M Henriksen; Lars T Jensen; Katja Krabbe; Per Guldberg; Tom Teerlink; Egill Rostrup
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.